Project number | Project title | PI | Date of approval |
PMCLAB2018.000 | The Máxima Genome Program | Prof.dr. Holstege/ Dr. Tops / Dr. Kemmeren |
16-Apr-18 |
PMCLAB2018.001 | Dexa-dagen 2 studie (SKION OC 2017-022) | Prof.dr. van den Heuvel-Eibrink | 14-Nov-17 |
PMCLAB2018.002 | MTX-FO studie (SKION OC 2018-006) | Prof.dr. van den Heuvel-Eibrink | 13-Mar-18 |
PMCLAB2018.004 | Development of in vitro and in vivo research models for pediatric brain tumors | Dr. Hulleman | 2-Jul-18 |
PMCLAB2018.005 | Generation of organoid models from patient-derived renal and rhabdoid tumors for the development of novel therapies | Dr. Drost | 19-Jul-18 |
PMCLAB2018.006 | Generation of organoid models from patient-derived renal tumors for the development of novel therapies | Dr. Drost | 19-Jul-18 |
PMCLAB2018.007 | Tracking the clonal origin of childhood acute myeloid leukemia | Dr. van Boxtel | 19-Jul-18 |
PMCLAB2018.008 | Identification of translocation-specific gene expression, alternative splicing and non-coding RNA signatures in high-risk pediatric leukemias | Dr. Stam | 19-Jul-18 |
PMCLAB2018.009 | Pediatric sarcoma tumoroid and single cell RNAseq analyses | Prof.dr. Holstege/Dr. van de Wetering/ Dr. Janda | 19-Jul-18 |
PMCLAB2018.010 | Identification of novel drugs and drug targets for the treatment of patients harboring NUP98 gene rearrangements, a poor prognostic patient group in pediatric acute myeloid leukemia. | Dr. Stam | 19-Jul-18 |
PMCLAB2018.011 | WES-KidTs (Whole Exome Sequencing in children with Kidney Tumors) | Prof.dr. van den Heuvel-Eibrink | 19-Jul-18 |
PMCLAB2018.013 | Multi-platform analysis of TSC Subependymal Giant Cell Astrocytoma (SEGA) to identify novel therapeutic approaches | Dr. Aronica | 19-Jul-18 |
PMCLAB2018.014 | Clinical aspects of neural crest development and anti-GD2 biomarker study for visualization and prognostification in neuroblastoma patients. | Prof.dr. van Noesel | 19-Jul-18 |
PMCLAB2018.015 | Liquid-biopsy based tumor detection for rhabdomyosarcoma to improve risk stratification at diagnosis and to improve response evaluation upon treatment | Dr. Tytgat | 19-Jul-18 |
PMCLAB2018.016 | Detection of cooperative and mutually exclusive genetic alterations in pediatric cancer | Dr. Kemmeren | 19-Jul-18 |
PMCLAB2018.017 | SV detection/Improving detection of structural variation in pediatric cancer | Dr. Kemmeren | 4-Oct-18 |
PMCLAB2018.018 | FLOWSOM analysis of AML flow cytometric data | Dr. Phillipé/Dr. de Haas | 4-Oct-18 |
PMCLAB2018.019 | A comparison of new genomic technologies for detecting small structural variants | Prof.dr. Holstege | 28-Jan-19 |
PMCLAB2018.020 | Cancer Immunotherapy (CIT) Cohort | Dr. Dierselhuis | 28-Jan-19 |
PMCLAB2018.021 | The role of connective tissue growth factor (CTGF) as biomarker for Pediatric bone marrow failure. | Dr. Leguijt | 6-Dec-18 |
PMCLAB2018.022 | Somatic mutational footprints in tumors caused by DNA repair syndromes and congenital immunodeficiency syndromes | Dr. Kuiper | 6-Dec-18 |
PMCLAB2019.024 | Development of a cord blood stem cell-derived anti-AML dendritic cell vaccine: Towards powerful "anti-AML immunity" after cord blood transplantation | Dr. Plantinga/Dr. Nierkens | 31-Jan-19 |
PMCLAB2019.025 | Breaking steroid resistance for T-ALL: phospho-proteomics and inhibitor testing | Dr. Meijerink | 18-Jul-19 |
PMCLAB2019.026 | Mutational effects of chemotherapy on normal cells of childhood cancer survivors | Dr. van Boxtel | 31-Jan-19 |
PMCLAB2019.027 | Tracing the causes and consequences of DNA damage in single hematopoietic stem cells of human Fanconi anemia patients | Dr. Belderbos | 31-Jan-19 |
PMCLAB2019.028 | Unraveling pediatric AML without a known driver | Dr. Noort | 31-Jan-19 |
PMCLAB2019.029 | Mechanisms of HOX-mediated Leukemogenesis in AML | Dr. Adriaanse | 4-Feb-19 |
PMCLAB2019.030 | Molecular characterization of pediatric germ cell tumors: towards clinical application | Dr. Looijenga | 9-May-19 |
PMCLAB2019.031 | Population dynamics of blood in Down syndrome-associated leukemia patients | Dr. van Boxtel | 28-Feb-19 |
PMCLAB2019.032 | Precusor B-cell acute lymphoblastic leukaemia with Ig-MYC translocation | Prof.dr. Vormoor | 21-Feb-19 |
PMCLAB2019.033 | Clonal heterogeneity and therapy resistance in Burkitt lymphoma | Dr.Loeffen/ Dr. Beishuizen | 21-Feb-19 |
PMCLAB2019.034 | Mapping CLOnal evolution by Next-generation sequencing in multi-relapsed Acute Lymphoblastic B-cell precursor leukemia (CLONAL-B) | Dr. Westera/Dr. de Haas | 28-Feb-19 |
PMCLAB2019.035 | Single cell analysis of pediatric medulloblastomas | Prof.dr. Stunnenberg | 28-Feb-19 |
PMCLAB2019.036 | Arterial and venous thrombosis in children, teenagers and young adults treated for acute lymphoblastic leukemia/lymphoma: a joint Ponte di Legno Toxicity Working Group/ iBFM study | Dr. van der Sluis | 28-Feb-19 |
PMCLAB2019.037 | A living neuroblastoma biobank with full molecular characterization | Dr. Molenaar | 14-Mar-19 |
PMCLAB2019.038 | The clinical and molecular genetic spectrum of immature T- and B-cell malignancies | Dr. Kroeze | 14-Mar-19 |
PMCLAB2019.039 | Bachelor thesis on effectivity of the ALL-10 treatment protocol; Research question: What is the influence of genetic abnormalities on different parameters, e.g. MRD and prednisone response in patients with T-cell acute lymphoblastic leukemia, treated by the ALL-10-protocol? | Dr. van den Berg | 11-Apr-19 |
PMCLAB2019.040 | Drug resistance profiling of children with ALL | Prof.dr. den Boer | 11-Apr-19 |
PMCLAB2019.041 | Digital image analysis by deep learning of Wilms tumors | Dr. de Krijger | 11-Apr-19 |
PMCLAB2019.042 | Use of quality indicators in neuroblastoma treatment: a feasibility assessment | Dr. Dijkstra | 25-Apr-19 |
PMCLAB2019.043 | IL-18 as diagnostic biomarker, differentiating systemic juvenile idiopathic arthritis from malignancies | Dr. Leek | 5-Dec-19 |
PMCLAB2019.044 | Opzetten TMA stainings | Dr. Stip | 9-May-19 |
PMCLAB2019.045 | Intensive care prevalence, morbidity, and survival in children with Wilms tumor in the Netherlands | Dr. Steur | 25-Apr-19 |
PMCLAB2019.046 | Incidence, clinical presentation and clinical outcome of invasive fungal diseases in childhood acute lymphoblastic leukemia (IFD ALL-11) | Dr. Bury | 9-May-19 |
PMCLAB2019.047 | The role for somatic evolution of mesenchymal stromal cells in the development of pediatric acute myeloid leukemia | Dr. van Boxtel | 9-May-19 |
PMCLAB2019.048 | Immunophenotype ETP-ALL | Dr. Cante - Barrett | 9-May-19 |
PMCLAB2019.049 | Onderzoek overleving van kinderen met een recidief ALL na stamceltransplantatie | Dr. Prinsze | 9-May-19 |
PMCLAB2019.050 | Surgery for Children with Cancer: Experience in a National Pediatric Oncology Center | Dr. Tien Lee | 20-Jun-19 |
PMCLAB2019.051 | Impact of cytogenetic aberrations on normal hematopoietic stem cells in acute myeloid leukemia. | Dr. Belderbos | 23-May-19 |
PMCLAB2019.052 | Prognosis of AML with ‘NUP98-other’ translocations | Dr. Goemans | 6-Jun-19 |
PMCLAB2019.053 | Comparison of FFPE-derived DNA and cell-free DNA from plasma in patients with pediatric rhabdomyosarcoma | Dr. Lak | 6-Jun-19 |
PMCLAB2019.054 | Mechanisms of hypermutation in relapsed acute lymphoblastic leukemia in children and implications for treatment | Dr. Kuiper | 18-Jul-19 |
PMCLAB2019.055 | Bulk and scRNA-seq of paediatric AML samples | Prof.dr. Heidenreich | 23-Sep-19 |
PMCLAB2019.056 | Congenital cutaneous AML | Dr. Goemans | 18-Jul-19 |
PMCLAB2019.057 | Ponte di Legno International Collaborative Leukemia Project Retrospective Investigation of NUT Midline Carcinoma Family Member 1 (NUTM1) rearrangements in Infants and Children with ALL | Dr. Boer | 18-Jul-19 |
PMCLAB2019.058 | The Role of mRNA splicing in Leukemic Stem and Progenitor Cells in Pediatric Acute Myeloid Leukemia | Dr. van der Werf | 30-Aug-19 |
PMCLAB2019.061 | Prevalence and Determinants of Tinnitus and Hearing Aid Use among 2,948 Dutch Survivors of Childhood Cancer: a DCOG Late-Effects Study | Dr. Meijer | 15-Aug-19 |
PMCLAB2019.062 | Identifying a second hit in the fumarate hydratase (FH) gene | Dr. Hol | 15-Aug-19 |
PMCLAB2019.063 | Single cell analysis of pediatric pheochromocytoma | Dr. Brazda | 15-Aug-19 |
PMCLAB2019.065 | Assessment of cLinical outcome, Epidemiology and Risk factors of renal Toxicity (ALERT studie) | Dr. Raymakers-Janssen | 29-Aug-19 |
PMCLAB2019.066 | Identifying molecular markers in peripheral blood of patients with pediatric renal tumors | Dr. Tytgat | 12-Sep-19 |
PMCLAB2019.067 | The metastatic bone marrow niche in Neuroblastoma | Dr. Tytgat | 12-Sep-19 |
PMCLAB2019.068 | A retrospective analysis of severely delayed methotrexate clearance in children with Acute Lymphoblastic Leukemia(ALL) | Dr. Oosterom | 26-Sep-19 |
PMCLAB2019.069 | Osteonecrosis in children and adolescents with Philadelphia chromosome positive acute lymphoblastic leukemia(Phi+ALL) treated with tyrosine kinase inhibitors (TKIs) in the EsPhALL protocols: incidence, risk factors, management and outcome. Contribution to a retrospective multicenter study, within the EsPhALL trials | Prof.dr. van den Heuvel-Eibrink | 26-Sep-19 |
PMCLAB2019.070 | Autologe stamceltransplantatie bij pediatrisch oncologische patiënten; “Poor Mobilisers”, Plerixafor en (PEG)filgrastim | Dr. Kraal | 26-Sep-19 |
PMCLAB2019.071 | Visual impairment in children with a brain tumor detected via unstructured ophthalmology screening : a retrospective cohort study | Dr. Schouten | 10-Oct-19 |
PMCLAB2019.073 | Analysis of CD37 expression in pediatric mature B‐cell lymphomas and correlation with clinical presentation and outcome | Dr. Meyer-Wentrup | 7-Nov-19 |
PMCLAB2019.074 | The bone marrow niche revisited: secretome profiling of pediatric ALL and AML | Prof.dr. den Boer | 7-Nov-19 |
PMCLAB2019.075 | Neuroblastoma European Catecholamine Study | Dr. Tytgat | 24-May-20 |
PMCLAB2019.076 | Physical performance in children with (supra)sellar tumors and hypothalamic dysfunction | Dr. Rehorst-Kleinlugtenbelt | 21-Nov-19 |
PMCLAB2019.077 | Generation of Hodgkin’s lymphoma organoids for functional studies | Dr. Meyer-Wentrup | 21-Nov-19 |
PMCLAB2019.079 | CARs for CNS-Leukemia Relapse: A retrospective international study proposal | Dr. Vormoor-Burger | 5-Dec-19 |
PMCLAB2019.080 | Characteristics of the neuro-vascular unit of the pons in patients suffering from diffuse intrinsic pontine glioma and healthy children | Dr. El-Khouly | 5-Dec-19 |
PMCLAB2019.081 | Identifying Minimal Residual Disease targets by FUDGE, a rapid Nanopore-sequencing based fusion-gene detection assay | Dr. Westera | 5-Dec-19 |
PMCLAB2019.082 | Benign and malignant skin disorders in CCS: the LATER SKIN cohort study | Prof.dr. Kremer | 5-Dec-19 |
PMCLAB2019.084 | Limbic system damage and neuropsychological outcomes in pediatric posterior fossa tumors | Dr. Partanen | 5-Dec-19 |
PMCLAB2019.085 | Screening of neuropsychological impairments in pediatric brain tumor | Dr. Partanen | 5-Dec-19 |
PMCLAB2019.086 | Detecting fibronectin splice-variants in osteosarcoma tumors | Dr. Janda | 19-Dec-19 |
PMCLAB2019.087 | Detection of high risk cancer predisposing genes | Dr. Kuiper | 13-Feb-20 |
PMCLAB2020.088 | Morphology of Burkitt lymphoma | Dr. Vermeulen | 16-Jan-20 |
PMCLAB2020.089 | The contribution of surgical clips for optimizing image-guided radiotherapy in pediatric renal tumors: the Utrecht experience | Prof.dr. van den Heuvel-Eibrink / Dr. Mul | 16-Jan-20 |
PMCLAB2020.090 | In-vitro models for rare pediatric cancers | Prof.dr. Clevers / Dr.van de Wetering | 30-Jan-20 |
PMCLAB2020.092 | The mutational spectrum of immature T-cell malignancies | Dr. Meijerink / Dr. Kroeze | 30-Jan-20 |
PMCLAB2020.093 | Full molecular characterization of the Princess Máxima Neuroblastoma cohort | Dr. Molenaar /Dr. Langenberg | 10-Mar-20 |
PMCLAB2020.094 | Investigating the mutational spectrum of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) | Prof.dr. Holstege /Dr. Meister | 30-Jan-20 |
PMCLAB2020.095 | Risk factors and prognosis of disseminated pediatric low grade glioma | Prof.dr. Hoving /Dr. van den Bergen | 30-Jan-20 |
PMCLAB2020.096 | The feasibility to make a Neuroblastoma xenograft bearing mouse with intact immune system | Dr. Tytgat | 30-Jan-20 |
PMCLAB2020.097 | Immunomonitoring: Investigation of efficacy of GM-CSF and G-CSF to activate neutrophils | Dr. Tytgat | 30-Jan-20 |
PMCLAB2020.098 | Radiotherapy-related meningioma, cerebrovascular events, and cataract in childhood cancer survivors: A Dutch LATER cohort Study project | Prof.dr. Kremer | 30-Jan-20 |
PMCLAB2020.099 | Health problems after 3D-planned pediatric radiotherapy: A nation-wide cohort study | Prof.dr. Kremer | 30-Jan-20 |
PMCLAB2020.100 | RNAseq data from neuroblastoma. (Neuroblastoma cell of origin) | Prof.dr. Clevers / Dr.van de Wetering | 13-Feb-20 |
PMCLAB2020.101 | Cataloguing and characterizing chemotoxicities of B-ALL treatment in Down syndrome children | Dr. van Boxtel/ Dr. Hasaart | 13-Feb-20 |
PMCLAB2020.102 | An International Study on Pediatric PICALM-MLLT10 + Leukemias | Dr. Goemans | 13-Feb-20 |
PMCLAB2020.103 | Risk factors and consequences of thyroid dysfunction after treatment for childhood cancer : filling the gaps in evidence needed for new international recommendations. The Dutch LATER cohort thyroid dysfunction study. (LATER THYR) | Prof.dr. Kremer/Dr. van Santen | 13-Feb-20 |
PMCLAB2020.104 | The incidence of influenza infections and risk factors for severe disease in children with cancer | Prof.dr. Tissing | 13-Feb-20 |
PMCLAB2020.105 | Validation of the molecular profiling pipeline at the Princess Máxima Center within the Princess Máxima Center precision medicine program iTHER | Dr. Molenaar | 23-Mar-20 |
PMCLAB2020.106 | Identification of genomic signatures predictive of AML outcome in paediatric patients | Prof.dr. Zwaan | 27-Feb-20 |
PMCLAB2020.107 | Towards understanding pediatric liver tumors | Dr. Peng | 27-Feb-20 |
PMCLAB2020.108 | The validation of the SARC-F child: a screenings tool in pediatric oncology | Prof.dr. van den Heuvel-Eibrink | 27-Feb-20 |
PMCLAB2020.109 | Adult growth hormone deficiency in childhood cancer survivors. | Prof.dr. van den Heuvel-Eibrink | 18-Jun-20 |
PMCLAB2020.110 | Metabolic syndrome in childhood cancer survivors (DCOG LATER METS study) | Prof.dr. van den Heuvel-Eibrink | 18-Jun-20 |
PMCLAB2020.111 | Frailty, impaired bone mineral density, fractures and follow-up of osteonecrosis in childhood cancer survivors (DCOG LATER BONE study) | Prof.dr. van den Heuvel-Eibrink | 18-Jun-20 |
PMCLAB2020.112 | Mutational dynamics between primary and relapse tumors of patients within the Princess Máxima Center precision medicine program iTHER | Dr. Molenaar | 3-Apr-20 |
PMCLAB2020.113 | Creation of a Tissue Micro-Array of primary Neuroblastoma samples | Dr. Molenaar | 27-Feb-20 |
PMCLAB2020.114 | Identifying the causal mechanism behind (no-known-driver) pediatric acute myeloid leukemia | Dr. van Boxtel | 12-Mar-20 |
PMCLAB2020.116 | Fusion gene detection using nanopore sequencing | Dr.Tops/ Dr. Monroe | 12-Mar-20 |
PMCLAB2020.118 | FFPE-derived DNA for target identification in cell-free DNA in patients with neuroblastoma | Dr. Tytgat | 12-Mar-20 |
PMCLAB2020.119 | A nationwide descriptive study of genetic predisposition in children with cancer: evaluation of diagnostic processes and consequences for clinical management | Dr. Kuiper/Dr. Jongmans | 26-Mar-20 |
PMCLAB2020.120 | Presence of scRNA sequencing markers in neuroblastoma patients | Prof.dr. Clevers / Dr.van de Wetering | 26-Mar-20 |
PMCLAB2020.121 | Benefits and limitations of implementation of a clinical decision support system (CDSS) to optimize drug dosing in paediatric oncology patients with impaired renal function (SIGNPOST) | Dr. Muilwijk | 26-Mar-20 |
PMCLAB2020.122 | Cerebrospinal fluid leakage after intradural surgery in the pediatric population – A retrospective cohort study | Prof.dr. Hoving | 9-Apr-20 |
PMCLAB2020.123 | A descriptive study of gliomas in children with Li Fraumeni syndrome | Dr. Jongmans | 9-Apr-20 |
PMCLAB2020.124 | Tumor-infiltrating lymphocytes in Neuroblastoma | Dr.Molenaar/Dr.Tytgat/Dr.van Noesel | 16-Apr-20 |
PMCLAB2020.125 | Effects of different formulations on Standardised Uptake Value measurements in Pediatric PET imaging | Dr. Merks/ Dr. de Keizer | 23-Apr-20 |
PMCLAB2020.126 | Clinical outcome of second relapsed and refractory first relapsed pediatric AML. A retrospective study within the NOPHO-DB SHIP consortium | Prof.dr. Kaspers | 23-Apr-20 |
PMCLAB2020.127 | Training MRI data for development of a semi-automated MRI analysis tool; part of the international retrospective DW-MRI rhabdomyosarcoma study project | Dr. Merks | 23-Apr-20 |
PMCLAB2020.128 | Exploring the origin of extramedullary pediatric acute myeloid leukemia. | Dr. van Boxtel | 7-May-20 |
PMCLAB2020.129 | Detection of cell surface antigens in rhabdomyosarcoma | Dr. Janda | 7-May-20 |
PMCLAB2020.130 | Patient-derived models to study disease biology and the therapeutic potential of gene therapy in Diamond-Blackfan Anemia. | Dr. de Haas | 26-May-20 |
PMCLAB2020.131 | Longitudinal patterns of quality of life during and after cancer treatment | Dr. Partanen/ Prof. dr. Grootenhuis | 25-May-20 |
PMCLAB2020.132 | Germline PAX5 alterations in pediatric ALL | Dr. Kuiper/Dr. Jongmans | 25-May-20 |
PMCLAB2020.133 | DMTR: Dutch Melanoma Treatment Registry | Dr. Zsiros | 22-Jun-20 |
PMCLAB2020.134 | Characteristics and outcome of children with renal tumors in the Netherlands, the first full five years experience of national centralization in the Princess Máxima Center for pediatric oncology, a descriptive national study. | Prof.dr. van den Heuvel-Eibrink | 4-Jun-20 |
PMCLAB2020.135 | Functional analyses of leukaemic lineage switches and MPALs | Prof.dr. Heidenreich | 4-Jun-20 |
PMCLAB2020.136 | Extracellular vesicles in patients with neuroblastoma: standardization and characterization | Dr. Tytgat | 22-Jun-20 |
PMCLAB2020.137 | TransExpo: International Study of Childhood Leukemia and Residences Near Electrical Transformer Rooms | Dr. Karim | 18-Jun-20 |
PMCLAB2020.139 | Natural history and prognostic factors of incidentelomas | Prof.dr. Hoving | 18-Jun-20 |
PMCLAB2020.141 | Targeting the central nervous system in MLL-rearranged infant acute lymphoblastic leukemia | Dr. Stam | 18-Jun-20 |
PMCLAB2020.142 | Pediatric brain tumor research at the Princess Maxima Center | Dr. Kool | 2-Jul-20 |
PMCLAB2020.143 | Psychosocial functioning of Dutch children with cancer and their parents during the COVID-19 pandemic | Prof.dr. Grootenhuis | 18-Jun-20 |
PMCLAB2020.144 | Analysis of markers of neurons in the adult human adrenal medulla | Dr. Molenaar | 18-Jun-20 |
PMCLAB2020.145 | Identifying cause of therapy failure in BCR-ABL 1 positive and BCR-ABL 1-like ALL. | Prof.dr. den Boer | 2-Jul-20 |
PMCLAB2020.146 | Clostridioides difficile in pediatric cancer and hematopoietic stem cell transplantation. | Prof.dr. Tissing | 2-Jul-20 |
PMCLAB2020.148 | Brain tumors in pediatric patients with neurofibromatosis type 1 in care or follow-up in a national pediatric oncologic center (a cohort study). | Prof.dr. Hoving | 2-Jul-20 |
PMCLAB2020.149 | Further development of kidney organoid culture: towards clinical applications | Dr. Drost | 2-Jul-20 |
PMCLAB2020.150 | Filling the gaps in evidence on prevalence, risk and surveillance for thyroid nodules and thyroid cancer in childhood cancer survivors (LATER THYR II). | Prof.dr. Kremer | 4-Aug-20 |
PMCLAB2020.151 | Identifying the mechanisms underlying therapy-related pediatric AML. | Dr. van Boxtel | 16-Jul-20 |
PMCLAB2020.152 | Added value of ASL perfusion MRI and 1H MRS in diagnosing and follow up of children with a brain tumor | Prof.dr. Hoving | 16-Jul-20 |
PMCLAB2020.153 | Genomic analysis of myofibromatosis. | Dr. Merks | 16-Jul-20 |
PMCLAB2020.154 | Cell free detection of hypermethylated RASSF1A in pediatric solid tumors. | Dr. Tytgat | 16-Jul-20 |
PMCLAB2020.155 | Ponte di Legno International Collaborative Leukemia Project; Retrospective investigation of tumor genetics in children with ETV6-RUNX1 positive ALL | Prof.dr. Pieters/Prof.dr. den Boer | 16-Jul-20 |
PMCLAB2020.156 | A retrospective analysis of the effect of inotuzumab ozogamicin on CAR-T cell treatment in B-cell precursor ALL. | Prof.dr. Zwaan | 16-Jul-20 |
PMCLAB2020.157 | Testis Sparing Surgery in Pediatric Testicular Tumors | Prof.dr. van Noesel | 16-Jul-20 |
PMCLAB2020.158 | Development of an in vitro culture system for pre-pubertal spermatogonial stem cells. | Dr. Looijenga | 16-Jul-20 |
PMCLAB2020.160 | Detection of mutational processes in acute lymphoblastic leukemia | Dr. Kuiper | 16-Jul-20 |
PMCLAB2020.161 | Improving diagnostics and therapy response of TP53 aberrant ALL | Dr. van Leeuwen/ Dr. Kuiper | 16-Jul-20 |
PMCLAB2020.162 | Risk and time trends of subsequent tumors after five decades of pediatric cancer treatment | Prof.dr. Kremer | 27-Aug-20 |
PMCLAB2020.163 | Imaging features of hepatic sinusoidal obstruction syndrome or veno-occlusive disease in children –a pictorial essay | Prof.dr. van Noesel | 27-Aug-20 |
PMCLAB2020.164 | Unraveling the immune microenvironment of ependymomas | Prof.dr. Hoving | 27-Aug-20 |
PMCLAB2020.165 | Immunoglobulin and T-cell receptor rearrangement detection in RNAseq, WES and WGS datasets | Dr. Tops | 10-Sep-20 |
PMCLAB2020.168 | Lineage cell tracing in histiocytosis patients | Prof.dr. Heidenreich | 24-Sep-20 |
PMCLAB2020.170 | Completing the information database of Nijmegen patient samples | Dr. Kuiper | 8-Oct-20 |
PMCLAB2020.171 | DWI-MRI based personalized tumor discrimination in children with renal tumors. | Prof.dr. van den Heuvel-Eibrink | 8-Oct-20 |
PMCLAB2020.172 | Impact of Conditioning, Graft Manipulation and Source on Outcomes after Transplantation for Fanconi anemia | Dr. Bierings | 8-Oct-20 |
PMCLAB2020.173 | Panel-of-normals for copy number and structural variant detection in WES and WGS data | Dr. Kuiper | 8-Oct-20 |
PMCLAB2020.174 | Develop and validate a pharmacokinetic model for high-dose methotrexate and quantification of the exposure-toxicity relationship in order to better predict and prevent severe methotrexate toxicity. | Dr. Hanff | 22-Oct-20 |
PMCLAB2020.175 | MRI changes after proton and photon therapy for primary pediatric CNS tumors in The Netherlands. | Prof.dr. Hoving | 30-Oct-20 |
PMCLAB2020.176 | Pediatric T-cell Acute Lymphoblastic Leukemia in the Netherlands: a population-based study over a 40 year period | Prof.dr. Pieters | 27-Oct-20 |
PMCLAB2020.177 | Health-related quality of life and its determinants in pediatric acute myeloid leukemia | Prof.dr. Grootenhuis | 22-Oct-20 |
PMCLAB2020.178 | Survival outcomes after relapse of myeloid leukemia in children with down syndrome | Dr. Goemans | 21-Dec-20 |
PMCLAB2020.179 | Immunohistochemical evaluation of CD99, CXCR4, NPY-R-Y1, LINGO-1, IGF-1R, C-Kit (CD117), NOTCH-R, Occludin and Claudin-1 for fluorescence-guided surgery (FGS) of Ewing sarcoma. | Prof.dr.Wijnen | 19-Nov-20 |
PMCLAB2020.180 | Registry of Chimeric Antigen Receptor T cell recipients with SARS-CoV-2 infection | Prof.dr. Vormoor | 18-Nov-20 |
PMCLAB2020.181 | Clinical course and molecular characterization of a retrospective nation-wide cohort of Dutch pediatric CNS germ cell tumors | Dr. Looijenga | 5-Nov-20 |
PMCLAB2020.182 | Histological and molecular characterization of extracranial germ cell tumors: towards an optimal patient risk stratification. | Dr. Looijenga | 5-Nov-20 |
PMCLAB2020.183 | ABDOMINAL NEUROBLASTOMA – Estimation of the clinical benefit of proton therapy based on literature review with validation of the Dutch single center cohort 2015-2020. | Prof.dr. van Noesel | 5-Nov-20 |
PMCLAB2020.184 | Isolation of mesenchymal stromal cells and haematopoietic stem and progenitor cells from human bone marrow | Prof.dr. Heidenreich | 19-Nov-20 |
PMCLAB2020.185 | CloFluBu conditioning in HCT for pediatric leukemia | Dr. Bierings | 5-Nov-20 |
PMCLAB2020.186 | Time trends in incidence and survival of thyroid carcinoma in children, adolescents and young adults (0-24 years) in the Netherlands, 1990-2018 | Prof.dr. van Noesel | 19-Nov-20 |
PMCLAB2020.187 | Survival of children, and adolescents and young adults (AYAs) with acute myeloid leukemia (AML) in the Netherlands | Prof.dr. Zwaan | 19-Nov-20 |
PMCLAB2020.188 | The thymus as resource of mediastinal germ cell tumors. | Dr. Looijenga | 19-Nov-20 |
PMCLAB2020.190 | Identification of novel tumor-specific proteins and epitopes across pediatric tumor types | Dr. van Heesch | 3-Dec-20 |
PMCLAB2020.191 | Time trends in incidence, stage at diagnosis, treatment and survival of sarcomas diagnosed in children and young adolescents (<18 years) in the Netherlands, 1990-2019 | Dr. Merks | 3-Dec-20 |
PMCLAB2020.193 | Treatment with chemotherapy in (relapse/progressive) pilocytic astrocytome: a multicenter retrospective cohort study. | Prof.dr. Hoving | 21-Dec-20 |
PMCLAB2020.194 | Outcome for children with acute myeloid leukemia in the Netherlands following initial treatment between 1998 and 2018 | Prof.dr. Zwaan | 10-Dec-20 |
PMCLAB2020.195 | Uitkomsten van directe lijn wissels versus een lijnvrij interval na centrale lijn verwijdering i.v.m. een centrale lijn geassocieerde bloedbaan infectie in kinderoncologie patiënten. | Prof.dr.Wijnen | 17-Dec-20 |
PMCLAB2020.196 | Dose-evaluation of antifungal treatment with isavuconazole in pediatric oncology patients (DEFINE) | Prof.dr. Tissing | 17-Dec-20 |
PMCLAB2021.199 | Imaging of neuroblastoma and correlation with other diagnostic techniques | Dr. Tytgat | 7-Jan-21 |
PMCLAB2021.200 | Cancer penetrance in patients with germline pathogenic variants in SMARCA4 | Dr. Jongmans | 7-Jan-21 |
PMCLAB2021.201 | Hypothalamic function and its relation to BMI change in children with brain tumors | Prof. Dr. Tissing | 7-Jan-21 |
PMCLAB2021.202 | Evaluation of b-SSFP as non-contrast MRA for surgical planning of Wilms tumour surgery | Prof. Dr. Wijnen | 7-Jan-21 |
PMCLAB2021.203 | Machine learning based MRI segmentation for 3D visualization in Wilms tumor planning | Prof. Dr. Wijnen | 7-Jan-21 |
PMCLAB2021.204 | Improved histological and molecular characterization of pediatric central nervous system tumors | Dr. Tops | 21-Jan-21 |
PMCLAB2021.206 | The role of functional imaging (FDG-PET and DW-MRI) in children and adolescents with an osteosarcoma or Ewing sarcoma | Dr. Merks | 21-Jan-21 |
PMCLAB2021.207 | Communication in the AML niche and its impact on treatment response | Prof. Dr. Heidenreich | 4-Feb-21 |
PMCLAB2021.208 | Risk of Central-Line Associated Bloodstream Infections in Pediatric Neuroblastoma Patients Receiving Immunotherapy | Prof. Dr. Wijnen | 21-Jan-21 |
PMCLAB2021.209 | Early detection of lymphoma in CMMRD and AT patients | Dr. Kuiper | 4-Feb-21 |
PMCLAB2021.210 | The transition of lymphoblastic malignancies: when does leukemia become lymphoma and vice versa? | Dr. Meijerink | 4-Feb-21 |
PMCLAB2021.211 | Predictors for malignancy in children with lymphadenopathy | Dr. Meyer-Wentrup | 4-Feb-21 |
PMCLAB2021.212 | MRD monitoring during maintenance in pediatric patients with acute lymphoblastic leukemia | Prof. Dr. Pieters | 18-Feb-21 |
PMCLAB2021.214 | Investigating the relationship between RNA alterations and upstream genomic events in pediatric cancer | Dr. Kemmeren | 18-Feb-21 |
PMCLAB2021.215 | RNA-seq based tumor classification for a broad range of pediatric cancer types | Dr. Kemmeren | 18-Feb-21 |
PMCLAB2021.216 | Detection and monitoring of cell free tumor DNA in plasma of infants with KMT2A-rearranged ALL | Prof.dr. Pieters | 4-Mar-21 |
PMCLAB2021.217 | Clinical relevance of a hotspot at the central venous access device tip on FDG PET-CT in pediatric oncology patients | Prof.dr. Pieters | 4-Mar-21 |
PMCLAB2021.218 | Efficacy of Imatinib in ABL-class fusion positive ALL | Prof.dr. den Boer | 4-Mar-21 |
PMCLAB2021.219 | Proposal for use of biobank patient materials for dedicated study related to patientcare | Dr. Tops/Dr. de Haas | 4-Mar-21 |
PMCLAB2021.220 | Immunofluorescent evaluation of CXCR4, NCAM, Jagged1, GJA-1 and Cadherin11 for fluorescence-guided surgery (FGS) of Wilms tumor | Prof.dr. Pieters | 18-Mar-21 |
PMCLAB2021.221 | A retrospective study on the use of CAR T-cells after Inotuzumab Ozogamicin treatment in children with relapsed or refractory acute lymphoblastic leukemia (ALL) | Prof.dr. Zwaan | 18-Mar-21 |
PMCLAB2021.222 | Palliative Care in a National Pediatric Oncology Center in the Netherlands: results of the first 18 months | Prof.dr. Tissing | 18-Mar-21 |
PMCLAB2021.223 | Evaluation of risk stratification based on genetic markers of ALL cases in the ALLTogether protocol | Prof.dr. den Boer | 18-Mar-21 |
PMCLAB2021.224 | Retrospective analysis of treatment outcomes of acute promyelocytic leukemia in Dutch children from 2005 until 2021 | Prof.dr. Kaspers | 1-Apr-2021 |
PMCLAB2021.225 | Regeneration of the human hematopoietic stem cell niche after transplantation | Dr. Belderbos | 1-Apr-2021 |
PMCLAB2021.226 | Getting on my nerves: Neural regulation of human hematopoietic stem cells | Dr. Belderbos | 1-Apr-2021 |
PMCLAB2021.228 | Tumor-specific transcripts as novel biomarkers and immunotherapy targets for pediatric cancer | Dr. van Heesch | 15-Apr-2021 |
PMCLAB2021.229 | Evolutionarily young microproteins in childhood brain cancer | Dr. van Heesch | 1-Apr-2021 |
PMCLAB2021.230 | Incidence of (Viridans Group Streptococci) bloodstream infections in children with acute myeloid leukemia treated at the Dutch Princess Máxima Center for Pediatric Oncology | Prof.dr. Kaspers | 1-Apr-2021 |
PMCLAB2021.231 | Is partial nephrectomy possible? An analysis of MRI imaging pre- and post-chemotherapy | Prof.dr. Pieters | 15-Apr-2021 |
PMCLAB2021.232 | Identification of a pLGG relevant MAPK activity score to predict response to MAPKi | Prof.dr. Hoving | 15-Apr-2021 |
PMCLAB2021.233 | De meerwaarde van het scannen van een MRI craniospinale as bij follow up van kinderen met een medulloblastoom, een retrospectief onderzoek. | Prof.dr. Hoving | 29-Apr-2021 |
PMCLAB2021.234 | Risk of second cancers in pediatric Hodgkin lymphoma patients: effects of treatment, age at diagnosis and attained age. | Prof.dr. Kremer | 20-Mei-2021 |
PMCLAB2021.235 | Risk factors for organ dysfunction and adverse outcome in pediatric oncology patients admitted to the pediatric intensive care unit | Prof.dr. Tissing | 29-Apr-2021 |
PMCLAB2021.236 | Pharmacogenetics in Pediatric Oncology: a case report of 10 patients | Dr. Huitema | 29-Apr-2021 |
PMCLAB2021.237 | Extent of resection in relation to anatomical location of pediatric brain tumors | Prof.dr. Hoving | 20-Mei-2021 |
PMCLAB2021.238 | Uncovering the spatial immune landscape in AML and “normal” hematopoiesis | Prof.dr. Heidenreich | 20-Mei-2021 |
PMCLAB2021.239 | AML Data commons, data request for the DB-AML01 protocol data | Prof.dr. Zwaan | 27-Mei-2021 |
PMCLAB2021.240 | iTHER 2.0: Clinical implementation of a pediatric cancer precision medicine program, enforced with personalized models | Prof.dr. Zwaan | 20-Mei-2021 |
PMCLAB2021.241 | Diffusion MRI in pediatric posterior fossa brain tumors | Prof.dr. Hoving | 20-Mei-2021 |
PMCLAB2021.242 | Using Whole Exome Sequencing for Pharmacogenetic Screening in Pediatric Oncology | Dr. Huitema | 20-Mei-2021 |
PMCLAB2021.243 | Expression data analysis to identify markers associated with extramedullary disease in ALL | Dr. Tops | 10-Jun-2021 |
PMCLAB2021.244 | Therapeutic drug monitoring of itraconazole and its main metabolite administered as prophylaxis in pediatric oncology patients | Dr. Hanff | 10-Jun-2021 |
PMCLAB2021.245 | Reducing survival disparities between pediatric, adolescent, and young adult patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) in the Netherlands | Prof.dr. Zwaan | 5-Aug-2021 |
PMCLAB2021.246 | Validation of cell-state marker genes identified by single-cell RNA-sequencing of rhabdomyosarcoma tumors | Prof.dr. Holstege | 10-Jun-2021 |
PMCLAB2021.247 | Treatment effect and toxicity evaluation of bevacizumab for progressive optic pathway glioma: a retrospective multicenter study | Prof.dr. Hoving | 10-Jun-2021 |
PMCLAB2021.248 | RNA-Based Diagnostic Tool for Pediatric MDS | Dr. Belderbos | 8-Jul-2021 |
PMCLAB2021.249 | Deciphering heterogeneity in T-ALL | Dr. Meijerink | 13-Sept-2021 |
PMCLAB2021.251 | Identification of residual T-ALL blasts in expanded ‘healthy’ T-cell subsets | Dr. Meijerink | 5-Aug-2021 |
PMCLAB2021.252 | A patient with second T-ALL with unique locations of the STIL-TAL1 fusion breakpoints at first and second leukemia presentation | Dr. Kuiper | 5-Aug-2021 |
PMCLAB2021.253 | Second line therapy outcomes in pediatric acute Graft-versus-host disease (STOPGvHD) | Dr. Lindemans | 27-Sept-2021 |
PMCLAB2021.254 | Characterization of Hodgkin lymphoma tumor cells and their microenvironment | Dr. van Boxtel | 8-Jul-2021 |
PMCLAB2021.255 | Prevalence and risk factors for taste alterations and nausea in children with cancer and the impact of these symptoms on Health Related Quality of Life (HRQoL) | Prof.dr. Tissing | 8-Jul-2021 |
PMCLAB2021.256 | International benchmarking of childhood cancer survival by tumour stage (BENCHISTA) | Dr. Karim | 5-Aug-2021 |
PMCLAB2021.257 | Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis | Prof.dr. Hoving | 5-Aug-2021 |
PMCLAB2021.258 | Retrospective analysis of RNAseq data from newly diagnosed and relapsed ALL and AML patients to develop insight and testable hypotheses on the communication of the leukemic cells with their microenvironment | Prof.dr. den Boer | 5-Aug-2021 |
PMCLAB2021.259 | Mutant BRAF allele burden in relation to clinical outcome: a multi-centre ECHO project | Prof.dr. Heidenreich | 5-Aug-2021 |
PMCLAB2021.260 | Spatial transcriptomic landscapes of high-grade pediatric brain tumors | Prof.dr. Stunnenberg | 30-Aug-2021 |
PMCLAB2021.261 | Request on data on Ectomesenchymoma | Dr. Merks | 19-Aug-2021 |
PMCLAB2021.262 | Multifactorial risk stratification for pediatric RMS | Prof.dr. Holstege | 19-Aug-2021 |
PMCLAB2021.263 | Defining central-line associated and central line related bloodstream infection in the hemato-oncological population | Prof.dr. Wijnen | 13-Sept-2021 |
PMCLAB2021.264 | Prognostic factors for survival after relapse in pediatric medulloblastoma: a retrospective Dutch cohort study | Prof.dr. Hoving | 13-Sept-2021 |
PMCLAB2021.265 | Investigating the clonal evolution of de novo pediatric AML | Dr. van Boxtel | 13-Sept-2021 |